Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): A randomised study

Bone Marrow Transplantation

Volumn 22, Issue 2, 1998, Pages 175-180

  Moretti, S ^a   Zikos, P ^a   Van Lint, M T ^a   Tedone, E ^a   Occhini, D ^a   Gualandi, F ^a   Lamparelli, T ^a   Mordini, N ^a   Berisso, G ^a   Bregante, S ^a   Bruno, B ^a   Bacigalupo, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

BMT; Foscarnet; Ganciclovir; HSCT

Indexed keywords

ANTIVIRUS AGENT; CREATININE; FOSCARNET; GANCICLOVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT FAILURE; VIREMIA; ALLOTRANSPLANTATION; COMPARATIVE STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOSCARNET; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 7344262512     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701302     Document Type: Article

References (28)

1. Meyers JD. Infection in bone marrow transplant recipients. Am J Med 1986; 81: 27.
2. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
3. Miller W, Flynn P, McCullough J et al. Cytoniegalovirus infection after bone marrow transplantation: an association with acute graft-versus-host-disease. Blood 1986; 67: 1162-1170.
4. Miller W, McCullough J, Balfour Jr HH et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood products screening. Bone Marrow Transplant 1991; 7: 227-234.
5. Bowden RA, Sayers M, Flournoy N et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplant, New Engl J Med 1986; 314: 1006-1010.
6. Ruutu T, Ljungman P, Brinch L et al. No prevention of cytomegalovirus infection by anticytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. Bone Marrow Transplant 1997; 19: 233-236.
7. Sullivan KM, Kopesky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. New Engl J Med 1990; 323: 705-712.
8. Goodrich JM, Boeckh M, Bowden R, Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994: 19: 287-298.
9. Prentice HG, Kho P. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant. Bone Marrow Transplant 1997: 19: 135-142.
10. Meyers J, Redd E. Shepp D et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. New Engl J Med 1988; 318: 70-75.
11. Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994: 343: 749-753.
12. Goodrich J, Bowden R A, Fisher L et al. Gancyclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
13. Winston JD, Winston G, Bartoni K et al. Gancyclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 178-184.
14. Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13: 783-788.
15. Goodrich JM, Mon M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991: 325: 1601-1607.
16. Schmidt GM, Horak DA, Niland JC et al. A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. New Engl J Med 1991; 324: 1005-1011.
17. Boeckh M, Gooley T, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
18. Gerna G, Furione M, Baldanti F et al. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. Br J Haematol 1995; 91(3): 674-63.
19. Bacigalupo A, van Lint MT, Tedone E et al. Early treatment, of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant 1994; 13: 753-758.
20. Bacigalupo A, Tedone E, Sonna MA et al. CMV infections following allogeneic BMT: risk factors early treatment and correlation with transplant-related mortality. Haematologica 1992; 77: 507-513.
21. Bacigalupo A, Bregante S, Tedone E et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 1996; 62: 376-380.
22. Bacigalupo A, Tedone E, Isuza A et al. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality. Bone Marrow Transplant 1995; 16: 155-161.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-460.
24. Ippoliti C. Morgan A, Warkentin D et al. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant 1997; 20: 491-495.
25. Ljungman P, Oberg G, Aschan J et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18: 565-568.
26. Ringden O, Pihlstedt P, Volin L et al. Failure to prevent cytomegalovirus infection by cytomegalovirus immune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 1987; 2: 299-305.
27. Razis E, Cook P, Mittelman A, Ahmed T. Treatment of ganciclovir resistant cytomegalovirus with foscarnet: a report of two cases occurring after bone marrow transplantation. Leuk Lymphoma 1994; 12: 477-480.
28. Reed E, Bowden R, Dandliker P et al. Treatment of cytomegalovirus pneumonia with gancyclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplantation. Ann Intern Med 1988; 109: 783-788.